トルコのトップエヴィプレラ医師と価格を比較。こちらで最適なマッチングを見つけてください
ご要望と予算に基づいて最適な医師を厳選いたします
医学的監修者 Fahad Mawlood
医学編集者・データサイエンティストトップ医師
3
トルコ
レビュー
14000+
実際の患者より
トップ各国のエヴィプレラ価格を比較
国をタップしてトップ医師と価格を表示
個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし
医師は19 Mayıs Universityで医学教育を修了し、S.B Heybeliada G.H.G.C. Teaching and Research Hospitalでレジデンシーを完了しました。トルコの複数の都市でのキャリアを経て、現在はHisar Intercontinental Hospitalで診療を行っています。医師は特に進行期COPDおよび肺気腫患者に対する診断および介入的気管支鏡検査を専門としています。医療の関心分野には、睡眠障害、喘息とアレルギー、COPD、結核、禁煙、肺癌、集中治療が含まれます。
GATA Haydarpaşa Training and Research Hospital Istanbul, Turkey
Residency program Sep 2011
Infectious Diseases and Clinical Microbiology Department fellowship program.
Gülhane Military Medical Academy Ankara, Turkey
Bachelor of Science: Medical School Aug 2003
Kuleli Military High School Istanbul, Turkey
High School Diploma Jul 1997
Health Sciences University Istanbul, Turkey
Associated Professor of Infectious Diseases Aug 2021 - Current
Associated Professor
Sisli Hamidiye Etfal Training and Research Hospital Istanbul, Turkey
Infectious Diseases Physician July 2020–August 2021
Infectious Diseases Physician
Yale School of Medicine Infectious Diseases Department New Haven, CT, USA
Associate Research Scientist June 2019- June2020
Research to improve vaccine against Tick Borne Diseases (Lyme Diseases, Babesiosis etc.)
Yale School of Medicine Infectious Diseases Department New Haven, CT, USA
Visiting Research Scientist Jul 2018 - June2019
Research to improve vaccine against Tick Borne Diseases (Lyme Diseases, Babesiosis etc.)
Turkish Ministry of Health Ankara, Turkey
Head of Health Tourism unit Feb 2017 - June 2018
Improving the health tourism policy of Turkey.
Sisli Hamidiye Etfal Training and Research Hospital Istanbul, Turkey
Infectious Diseases Physician Aug 2016 - June 2018
Infectious Diseases Physician
Tatvan Military Hospital Bitlis , Turkey
Infectious Diseases Physician Jul 2013 - Aug 2016
Infectious Diseases physician
Girne Military Hospital Turkish Republic of Northern Cyprus
Infectious Diseases Physician Oct 2011 - Jun 2013
Infectious diseases physician
GATA Training and Research Hospital Istanbul, Turkey
Residency period Jul 2006 - Sep 2011
4 th. Mechanized Infantry Brigade Command Edirne, Kesan, Turkey
Medical Doctor, May 2004 - Jun 2006
Maintaining the basic health services of the military unit.
Prof. Dr. Ali İnal is a physician with over 25 years of experience. He specializes in Clinical Microbiology, Infectious Diseases, Immunology, and Allergy. He works as a Professor in the Department of Immunology and Allergy at Başkent University Istanbul Hospital.
Dr. İnal completed his training in Clinical Microbiology and Infectious Diseases. He also finished a fellowship in Clinical Immunology and Allergy. He has managed Immunology and Tissue Typing Laboratories for more than 20 years. He has played a key role in improving transplant immunology and diagnostic immunology services.
His research covers cytokine storms in COVID-19, donor-specific antibodies, transplant rejection, autoimmunity, and primary immunodeficiencies. Dr. İnal has published many scientific articles. He has received research awards and grants. He also takes part in national and international congresses.
海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。
ヤン・マツィイフスキー
医療コーディネーターチーム責任者
4300+件以上の患者の旅をガイド
Bookimedで3年
Turkeyの278名の患者が今月当社を通じて医師を見つけました
2分のクイズ
目標、予算、スケジュールをお聞かせください
人間のマッチング + AI
アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します
オプション準備完了
価格、パッケージ、日程を比較。コーディネーターとチャット
選択肢に迷っていますか？
治療をガイド
医療訓練を受けた専属コーディネーター
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|
Eviplera is a single-tablet antiretroviral medication combining rilpivirine, emtricitabine, and tenofovir disoproxil to treat HIV-1. It works by blocking the reverse transcriptase enzyme, which prevents the virus from replicating and infecting new cells, effectively lowering the viral load in the bloodstream.
Bookimed Expert Insight: While Eviplera is highly effective, its rilpivirine component has a lower barrier to resistance than newer integrase inhibitors. Patients in Turkey often work with specialists like Associate Professor Husrev Diktas at Medipol Acibadem, who prioritize resistance genotyping before starting this specific regimen to ensure long-term success.
Patient Consensus: Many patients report vivid dreams or insomnia during the first month, though these effects typically fade. Consistency is vital, as missing doses with this specific drug combination significantly increases the risk of treatment resistance.
Commencing or switching to Eviplera in Turkey is safe when managed by infectious disease specialists at JCI-accredited facilities. While widely available in major pharmacies, non-citizens must pay out-of-pocket, with prices ranging from $900 to $1,400. Patients require a local prescription and baseline viral load monitoring.
Bookimed Expert Insight: While Eviplera costs $900 in Turkey, saving up to 76% vs US prices, the real advantage is the concentration of Yale-trained specialists in Istanbul. Associate Professor Husrev Diktas, who researched immunology at Yale, provides world-class oversight for complex medication switches.
Patient Consensus: Patients emphasize the importance of taking Eviplera with a full meal. They recommend visiting an HIV clinic first to secure a Turkish prescription and ensure pharmacy stock is available.
Starting Eviplera in Turkey requires mandatory diagnostic screenings to ensure patient safety and drug efficacy. Standard protocols involve HIV-1 RNA viral load testing, resistance profiling, and comprehensive organ function assessments. These tests verify the virus is susceptible to the medication and your body can process the treatment safely.
Bookimed Expert Insight: Turkish infectious disease specialists sometimes include TB screening (Quantiferon) as a routine pre-ART requirement. This is more rigorous than standard Western European protocols. Clinics like Emsey Hospital often coordinate these specific diagnostic panels within 24–48 hours to prevent delays in starting therapy.
Patient Consensus: Many patients suggest requesting a full Ministry of Health-compliant test list early. Fasting for lipid panels is often required and can cause unexpected delays if you are unprepared.
Specific medical conditions and drug interactions make Eviplera unsuitable for certain patients. Key exclusions include individuals with a viral load exceeding 100,000 copies/mL or known resistance to NNRTI medications. Patients with severe kidney or liver impairment and those under 18 years old should avoid this treatment.
Bookimed Expert Insight: HIV management in Turkey often involves highly specialized researchers like Associate Professor Husrev Diktas at Medipol Acibadem. He previously conducted vaccine research at Yale School of Medicine. This academic background ensures precise screening for complex contraindications that general practitioners might overlook.
Patient Consensus: Patients emphasize the need for thorough renal function testing before starting treatment. Experts suggest specialized screenings for neuropsychiatric history are essential to ensure the medication is safe for you.
Eviplera commonly causes gastrointestinal upset, dizziness, and sleep disturbances during the initial months of treatment. Patients must monitor for serious but rare complications like lactic acidosis and liver dysfunction. Regular bloodwork is required in clinics to track kidney health and metabolic changes effectively.
Bookimed Expert Insight: While side effects are a concern, specialist clinics in Istanbul like Emsey Hospital offer multidisciplinary support. Some patients manage initial stomach upset by using a bland diet and probiotics. Infectious disease experts like Associate Professor Husrev Diktas at Medipol Acibadem provide specialized HIV management to mitigate these risks.
Patient Consensus: Many reports highlight intense fatigue and mood swings in the first few months. However, several patients successfully maintain high energy levels and transition to zero side effects after their bodies adjust.
The standard follow-up schedule for Eviplera in Turkey includes a primary clinical assessment at 2 to 4 weeks to monitor renal function and drug tolerance. Stable patients transition to periodic laboratory checks every 3 to 6 months to evaluate viral load suppression and CD4 T-cell counts.
Bookimed Expert Insight: While European protocols are standard, selecting a specialist like Associate Professor Husrev Diktas at Medipol Acibadem District Hospital ensures access to Yale-trained expertise in HIV management. High-volume centers in Istanbul often provide faster laboratory results than rural state facilities, which is critical during the first month of treatment.
Patient Consensus: Many patients suggest tracking daily side effects like insomnia to discuss during the first month check-up. Those in large cities report faster access to viral load testing, while others emphasize strict adherence to the once-daily mealtime dosing.
Starting Eviplera therapy in Turkey requires a stay of 3 to 7 days. This period allows for a specialist consultation at a JCI-accredited facility, comprehensive baseline blood work, and monitoring for immediate side effects. Most patients initiate treatment within 24 to 72 hours of arrival.
Bookimed Expert Insight: While many expect immediate starts, arriving on a Tuesday or Wednesday is highly recommended. Our data shows that weekend laboratory closures in cities like Istanbul can unexpectedly add 2 days to your timeline. Securing a mid-week appointment ensures you receive results and the physical prescription without administrative delays.
Patient Consensus: Experienced travelers suggest budgeting for 1 or 2 extra hotel nights. They advise confirming the local pharmacy has the specific brand in stock before your flight to avoid logistical stress.